
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ibalizumab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : Theratechnologies
Deal Size : Undisclosed
Deal Type : Acquisition
Theratechnologies Announces Completion of Acquisition by Future Pak
Details : Trogarzo (ibalizumab) is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors.
Product Name : Trogarzo
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
September 25, 2025
Lead Product(s) : Ibalizumab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Theratechnologies
Deal Size : Undisclosed
Deal Type : Acquisition
